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Abstract
Introduction: Current attempts to identify genetic modifiers of BRCA1 and BRCA2 associated risk have focused on
a candidate gene approach, based on knowledge of gene functions, or the development of large genome-wide
association studies. In this study, we evaluated 24 SNPs tagged to 14 candidate genes derived through a novel
approach that analysed gene expression differences to prioritise candidate modifier genes for association studies.
Methods: We successfully genotyped 24 SNPs in a cohort of up to 4,724 BRCA1 and 2,693 BRCA2 female mutation
carriers from 15 study groups and assessed whether these variants were associated with risk of breast cancer in
BRCA1 and BRCA2 mutation carriers.
Results: SNPs in five of the 14 candidate genes showed evidence of association with breast cancer risk for BRCA1
or BRCA2 carriers (P < 0.05). Notably, the minor alleles of two SNPs (rs7166081 and rs3825977) in high linkage
disequilibrium (r
2 = 0.77), located at the SMAD3 locus (15q22), were each associated with increased breast cancer
risk for BRCA2 mutation carriers (relative risk = 1.25, 95% confidence interval = 1.07 to 1.45, Ptrend = 0.004; and
relative risk = 1.20, 95% confidence interval = 1.03 to 1.40, Ptrend = 0.018).
Conclusions: This study provides evidence that the SMAD3 gene, which encodes a key regulatory protein in the
transforming growth factor beta signalling pathway and is known to interact directly with BRCA2, may contribute
to increased risk of breast cancer in BRCA2 mutation carriers. This finding suggests that genes with expression
associated with BRCA1 and BRCA2 mutation status are enriched for the presence of common genetic modifiers
of breast cancer risk in these populations.
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BRCA1 and BRCA2 mutation carriers are at increased
risk for developing breast cancer and/or ovarian cancer.
Estimates of the cumulative risk of breast cancer by age
70 years range from 46% to 87% for BRCA1 mutation
carriers and from 43% to 84% for BRCA2 mutation car-
riers [1-6]. Evidence from these studies suggests that
breast cancer risks in mutation carriers are modified by
environmental or genetic factors. A number of large stu-
dies, facilitated through the Consortium of Investigators
of Modifiers of BRCA1/BRCA2 (CIMBA), have evaluated
associations between genetic polymorphisms and breast
cancer risk in BRCA1 and BRCA2 mutation carriers
[7-15].
The candidate gene (or candidate SNP) approach for
identifying potential risk modifiers has been successfully
u s e dt oi d e n t i f yaS N Pi nt h e5 ’ untranslated region of
RAD51. Until recently, this finding has provided the
most reliable evidence for a genetic modifier in BRCA2
mutation carriers [7]. A major disadvantage of using this
approach to identify common genetic modifiers of breast
cancer, however, is the limited understanding of
mechanisms and pathways that underlie breast cancer
development in families carrying mutations in BRCA1
or BRCA2. An alternative and powerful approach that
can overcome such issues is the use of genome-wide
association (GWA) studies to identify candidate SNPs.
Analysis of breast cancer risk-associated SNPs identified
by a large population-based GWA study of breast cancer
[16] has shown that several of these SNPs also appear to
modify risk in BRCA1 and/or BRCA2 mutation carriers
[8]. Not all of the breast cancer-associated SNPs
assessed have been found to modify risk in carriers,
however, and some of the risk associations are specific
for BRCA2 mutation carriers only and not BRCA1 [8].
While GWA studies specifically addressing risk for
BRCA1 and/or BRCA2 carriers are a more direct
approach to identifying modifiers of these genes using
an agnostic approach, GWA studies require large sam-
ple sizes to identify genetic modifiers with confidence.
To address the problem of inadequate sample size, the
CIMBA was established in 2005 to link clinical and epi-
demiological data from many groups from around the
world [17]. The GWA approach is still limited, however,
in that study designs involve predefined stringent selec-
tion criteria for which SNPs identified from the initial
whole genome scan are going to be analysed in subse-
quent replication studies, a study design enforced by
current genotyping costs. Moreover, GWA studies are
often limited in information about exogenous risk fac-
tors, such as environmental exposures, which confounds
any effort to explore the effect of environmental factors
in modifying gene-disease associations. Global gene
expression analysis as a means to agnostically identify
candidate genetic modifiers has the potential to priori-
tise SNPs for candidate genes for association studies.
T h i sm a yb ep a r t i c u l a r l yv a l u a b l eg i v e nr e c e n to b s e r v a -
tions that SNPs associated with risk of cancer in the
general population appear to reside in noncoding
regions that may modulate gene expression.
An alternative approach to prioritising SNPs and can-
didate genes for association studies in BRCA1 and
BRCA2 mutation carriers could rely on the selection of
genes displaying associations with BRCA1 or BRCA2
mutation status at the expression level in response to
DNA damage. In a previous study, we used a novel
combinatorial approach to identify a subset of 20 irra-
diation responsive genes as high-priority candidate
BRCA1 and/or BRCA2 modifier genes [18]. The expres-
sion levels of these genes were shown to be associated
with BRCA1 and/or BRCA2 mutation status in irra-
diated lymphoblastoid cell lines from female carriers
when compared against irradiated lymphoblastoid cell
lines from healthy controls. Furthermore, each of the
genes were tagged with one or more SNPs shown to be
associated with breast cancer risk from the Cancer
Genetic Markers of Susceptibility (CGEMS) Phase 1
Breast Cancer Whole Genome Association Scan [19,20].
In the present study we investigated the association of
these polymorphisms, tagged to genes demonstrated in
vitro to be involved in irradiation response, with risk of
breast cancer for BRCA1 and BRCA2 mutation carriers.
Materials and methods
Study participants
Eligibility of study participants was restricted to female
BRCA1 or BRCA2 pathogenic mutation carriers who
were aged 18 years or older. Fifteen clinic and popula-
tion-based research studies from the USA, Canada, Aus-
tralia, the UK and Europe submitted data to the present
study (Table 1). Information collected included year of
birth, age at diagnosis of breast cancer or ovarian can-
cer, age at last observation, family membership, ethnicity
and information on bilateral prophylactic mastectomy
and oophorectomy. All centres have obtained informed
consent from study participants and the institutional
review board approved protocols. In total, this study
included up to 4,724 BRCA1 and 2,693 BRCA2 eligible
female mutation carriers. Of the 2,193 and 1,189 unaf-
fected BRCA1 and BRCA2 carriers, respectively, 972
(44.3%) and 589 (49.5%) had a relative that was in the
affected group.
SNP selection and genotyping
In a previous report, we proposed 13 genes (ARHGEF2,
HNRPDL, IL4R, JUND, LSM2, MAGED2, MLF2,
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Page 2 of 10MS4A1, SMAD3, STIP1, THEM2, TOMM40, VNN2)a s
candidate modifiers of breast cancer risk for BRCA1
mutation carriers, and 14 genes (ARHGEF2, JUND,
MLF2, SMAD3, STIP1, THEM2, TOMM40, ABL1,
ELMO1, EPM2AIP1, PER1, PLCG2, PLD3, SLC20A1)a s
candidate modifiers of breast cancer risk for BRCA2
mutation carriers (see Additional file 1) [18]. Thirty-
seven SNPs denoted by CGEMS as being tagged to
these genes were initially identified as showing some
association with breast cancer risk (P < 0.05) (see Addi-
tional file 2). Of these 37 SNPs, a panel of 32 variants
were selected after successful assay design and geno-
typed on two platforms, using the Illumina GoldenGate
assay (Illumina Inc., San Diego, California, USA) and
the Sequenom MassARRAY iPLEX platform (Sequenom,
San Diego, CA, USA), as previously described [21,22].
The genotyping method used for each participating
study is detailed in Table 1. Five SNPs tagged to five
candidate genes (JUND, MAGED2, MLF2, MLH1,
STIP1) had call rates <95% and were excluded from the
analysis. The minor allele frequencies of three SNPs
(rs2893535 - ELMO1, minor allele frequency = 0.033;
rs2304911 - PER1, minor allele frequency = 0.043; and
rs3802957 - MS4A1, minor allele frequency = 0.04) were
considered too small for reliable analysis. The number
of genes assessed for their associations with breast can-
cer risk for BRCA1 and BRCA2 mutation carriers was
therefore eight and 10, respectively.
Statistical methods
Relative risks (RRs) and 95% confidence intervals were
estimated using weighted Cox proportional hazards
models. Each subject was followed from birth to the ear-
liest of breast cancer, bilateral mastectomy, ovarian can-
cer, last follow-up, or age 80. The phenotype of interest
was time to breast cancer. Mutation-specific weights
were calculated using the age distribution of affected
and unaffected individuals according to the methods
previously outlined by Antoniou and colleagues [23].
Analyses were stratified by year of birth, ethnicity, coun-
try of residence, study site, and mutation status. A
robust variance estimate was used to account for relat-
edness amongst individuals. Primary SNP analyses
assumed a log-additive relationship between the number
of minor alleles carried by each individual and time to
breast cancer. Wald P values below 0.05 were declared
of interest. Secondary analyses were carried out in
which RR estimates were separately generated for those
carrying one and two copies of the minor allele versus
those with two copies of the major allele. Between-study
heterogeneity was examined in each SNP by including
an interaction term between the genotype and study
centre.
Owing to the highly-selected nature of subjects, a
number of sensitivity analyses were examined. To limit
the effect of potential survival bias, subjects diagnosed
more than 5 years prior to study enrolment were
excluded (number affected analysed = 1,342 and 762 for
BRCA1 and BRCA2 carriers, respectively). Other models
were examined that excluded women with ovarian can-
cer (number excluded = 491 and 151 BRCA1 and
BRCA2 carriers, respectively). Finally, as risk of breast
cancer is reduced after bilateral oophorectomy [24,25],
analyses were carried out treating oophorectomy as a
time-dependent covariate in the Cox proportional
hazards models. All P values are two sided and analyses
were carried out using R software [26].
Results and Discussion
A cohort of up to 4,724 BRCA1 and 2,693 BRCA2
female mutation carriers was used for the present study.
Of these, 4,035 mutation carriers were diagnosed with
breast cancer or ovarian cancer at the end of follow-up
Table 1 Distribution of BRCA1 and BRCA2 mutation
carriers by study site
Study Country
a BRCA1 BRCA2 Genotyping
platform
HEBON The Netherlands 807 308 iPLEX
b; Golden
Gate
c
EMBRACE UK 841 656 iPLEX
b; Golden
Gate
c
FCCC USA 82 53 iPLEX
b; Golden
Gate
c
GC-HBOC Germany 398 163 Golden Gate
c
GEMO France/USA 408 226 Golden Gate
c
Georgetown USA 27 14 iPLEX
b; Golden
Gate
c
HEBCS Finland 103 104 iPLEX
b; Golden
Gate
c
ILUH Iceland 6 87 iPLEX
b; Golden
Gate
c
kConFab Australia/New
Zealand
531 427 iPLEX
b; Golden
Gate
c
Mayo USA 227 123 iPLEX
b; Golden
Gate
c
ModSQuaD USA 158 91 Golden Gate
c
MUV Austria 298 126 iPLEX
b; Golden
Gate
c
PBCS Italy 76 43 iPLEX
b
SWE-BRCA Sweden 489 141 iPLEX
b; Golden
Gate
c
UPENN USA 273 131 iPLEX
b; Golden
Gate
c
EMBRACE, Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers;
FCCC, Fox Chase Cancer Center; HEBON, Hereditary Breast and Ovarian Cancer
Research Group Netherlands; ILUH, Iceland Landspitali - University Hospital
Study; kConFab, Kathleen Cunningham Consortium for Research into Familial
Breast Cancer; ModSQuaD, Modifier Study of Quantitative Effects on Disease;
MUV, Medical University of Vienna; PBCS, Pisa Breast Cancer Study.
aCoordinating centre.
bSamples were genotyped at the Queensland Institute
of Medical Research.
cSamples were genotyped at the Mayo Clinic.
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Page 3 of 10and 3,382 were censored as unaffected at a mean age of
44 years. The patient characteristics of BRCA1 and
BRCA2 mutation carriers are presented in Table 2.
The RR estimates for the association between SNP
genotypes and risk of breast cancer for BRCA1 and
BRCA2 mutation carriers are presented in Table 3 and
Table 4 respectively. Of the 24 SNPs that passed quality
control, the minor alleles of two SNPs were found to be
associated with increased risk for BRCA1 mutation car-
riers (rs10242920 - ELMO1, P = 0.043; and rs480092 -
LSM2, P = 0.015) and the minor alleles of three SNPs to
be associated with increased risk for BRCA2 mutation
carriers (rs1559949 - HNRPDL, P = 0.021; rs3825977 -
SMAD3, P = 0.018; and rs7166081 - SMAD3, P = 0.004).
The minor alleles of two SNPs, rs1559949 (HNRPDL)
and rs3808814 (ABL1), were associated with decreased
risk for BRCA1 (P = 0.022) and BRCA2 (P = 0.030)
mutation carriers, respectively.
All SNPs selected for the present study (see Additional
f i l e2 )h a dp r e v i o u s l yb e e nr e p o r t e dt ob ea tl e a s tm a r -
ginally associated (P < 0.05) with breast cancer risk
through the CGEMS Phase 1 Breast Cancer Whole Gen-
ome Association Scan [18], and to be tagged to a gene
whose expression level was associated with BRCA1 and/
or BRCA2 mutation status in irradiated lymphoblastoid
cell lines [18]. The minor allele of four out of six SNPs
shown here to be associated with risk in BRCA1 muta-
tion carriers (rs1559949 - HNRPDL; rs480092 - LSM2)
or BRCA2 (rs3825977 and rs7166081 - SMAD3)h a d
risk estimates for the homozygous genotype that were
concordant with the odds ratio reported by the CGEMS
s t u d y( T a b l e3a n d4 ,a n dA d d i t i o n a lf i l e2 ) .F u r t h e r -
more, the expression of HNRPDL and LSM2 was asso-
ciated with BRCA1 mutation status and the expression
of SMAD3 was associated with BRCA2 mutation status
[18]. The risk estimate of rs10242920 (ELMO1) was also
concordant with the odds ratio determined by the
CGEMS study; and although the expression of ELMO1
was not associated with BRCA1 mutation status at P <
0.001, there was an association with gene expression at
P < 0.005 [18]. In contrast, the risk estimates of
rs3808814 (ABL1) and rs1559949 (HNRPDL)i nBRCA2
mutation carriers are not concordant with the odds
ratio determined by the CGEMS study. Forest plots of
study groups with 70 or more carriers and tests of het-
erogeneity are shown for two of the most significant
SNPs (rs3825977, P-het = 0.619 and rs7166081, P-het =
0.218 at the SMAD3 locus), stratified by study site (Fig-
ure 1). The minor alleles of rs3825977 and rs7166081
are in high linkage disequilibrium (r
2 = 0.77), which
would be expected if their association with increased
breast cancer risk is bona fide.
Although further study is required to confirm whether
genetic variation in SMAD3 plays a role in modifying risk
of breast cancer, SMAD3 has been shown to interact
with the BRCA2 protein - suggesting a possible mechan-
ism through which SMAD3 may modify BRCA2 function
[27]. Furthermore, SMAD3 is a critical regulatory factor
Table 2 Patient characteristics
Characteristic BRCA1 mutation carriers BRCA2 mutation carriers
Unaffected Breast cancer Unaffected Breast cancer
Number of carriers 2,193 2,531 1,189 1,504
Length of follow-up (person-years) 93,521 102,870 53,147 66,764
Mean (SD) age at censure (years) 43 (12.6) 41 (9.4) 45 (13.2) 44 (9.7)
Age at censure, n (%)
< 30 years 344 (16%) 252 (10%) 144 (12%) 52 (3%)
30 to 39 years 658 (30%) 1060 (42%) 343 (29%) 474 (32%)
40 to 49 years 608 (28%) 809 (32%) 331 (28%) 587 (39%)
50 to 59 years 374 (17%) 310 (12%) 215 (18%) 273 (18%)
60 to 69 years 143 (6%) 87 (3%) 101 (8%) 93 (6%)
70+ years 66 (3%) 13 (1%) 55 (5%) 25 (2%)
Year of birth, n (%)
Before 1949 523 (24%) 840 (33%) 281 (24%) 602 (40%)
1949 to 1959 508 (23%) 816 (32%) 307 (26%) 518 (35%)
1960 to 1968 594 (27%) 602 (24%) 302 (25%) 303 (20%)
After 1968 568 (26%) 273 (11%) 299 (25%) 81 (5%)
Oophorectomy 260 (12%) 77 (3%) 126 (11%) 47 (3%)
Ethnicity, n (%)
Caucasian 2127 (97%) 2446 (97%) 1159 (97%) 1464 (97%)
Ashkenazi Jewish 66 (3%) 85 (3%) 30 (3%) 40 (3%)
SD, standard deviation.
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known to play a key role in the development of breast
cancer as well as many other cancers [28,29]. In addition,
a recent study comparing dense breast tissue (a known
breast cancer risk factor) with nondense tissue identified
reduced expression of SMAD3 to be associated with
dense tissue, indirectly supporting a role of SMAD3
expression with breast cancer risk [29].
Choosing candidate BRCA1 and BRCA2 modifier
genes from a novel combinatorial approach [18], we
show that four SNPs tagged to three of the 14 candidate
genes show an association with breast cancer risk for
BRCA1 or BRCA2 mutation carriers. We initiated the
present study, however, with the expectation that SNPs
in eight of the 14 genes may be associated with altered
expression in BRCA1 mutation carriers, and 10 of the
14 genes with altered expression in BRCA2 carriers. We
can thus argue that three out of 18 (17%) valid compari-
sons showed an association with risk. For either inter-
pretation, the rate of observed association is greater
than the one in 20 (5%) expected by chance. In addition,
post hoc mining of the expression dataset showed that
another SNP (rs10242920 - ELMO1) association that
was consistent with the effect reported in the CGEMS
dataset was also actually associated with altered expres-
sion in carriers, albeit with less significance (P = 0.005)
than originally used for gene and SNP selection. These
findings suggest that the combinatorial approach may be
a useful method to prioritise candidate modifier genes
for polymorphism association studies. It is notable that
CIMBA GWA studies of BRCA1 and BRCA2 mutation
carriers are currently underway [30]. One might there-
fore anticipate that the combinatorial approach would
provide even greater enrichment for prioritising SNPs
from GWA studies that directly relate to the disease
state under study. Further studies with larger cohort
size are therefore warranted to assess the benefit of car-
rying out such an approach.
Conclusions
We have explored the value of using biological informa-
tion embedded in gene expression data to prioritise can-
didate modifier genes for SNP association studies. Using
this combinatorial approach we were able to demon-
strate a threefold enrichment of genes that contain
SNPs associated with breast cancer risk for BRCA1 or
BRCA2 mutation carriers. Most notable was the evi-
dence that the SMAD3 gene, which encodes a key
Table 3 Genotype distributions of 24 candidate modifier SNPs and hazard ratio estimates for BRCA1 mutation carriers
SNP Gene Minor allele MAF Heterozygous Homozygous Per allele Ptrend
HR 95% CI HR 95% CI HR 95% CI
rs7026988 ABL1 A 0.12 1.08 0.88 to 1.34 1.61 0.82 to 3.15 1.13 0.93 to 1.36 0.212
rs3808814 ABL1 A 0.09 0.90 0.72 to 1.14 0.65 0.22 to 1.91 0.89 0.72 to 1.10 0.284
rs1889532 ARHGEF2 G 0.25 0.99 0.83 to 1.18 1.12 0.80 to 1.56 1.03 0.90 to 1.18 0.708
rs10242920 ELMO1 A 0.24 1.06 0.89 to 1.27 1.61 1.12 to 2.32 1.16 1.00 to 1.33 0.043
rs6964474 ELMO1 C 0.22 1.08 0.90 to 1.29 0.71 0.49 to 1.02 0.96 0.84 to 1.10 0.568
rs2541095 ELMO1 G 0.12 1.03 0.84 to 1.27 1.12 0.48 to 2.63 1.04 0.86 to 1.26 0.683
rs6956864 ELMO1 G 0.41 1.04 0.76 to 1.42 1.35 0.18 to 10.03 1.05 0.78 to 1.42 0.755
rs1559949 HNRPDL G 0.14 0.78 0.65 to 0.94 0.91 0.51 to 1.64 0.82 0.70 to 0.97 0.022
rs4285076 HNRPDL A 0.29 0.95 0.80 to 1.12 1.00 0.73 to 1.37 0.98 0.86 to 1.11 0.746
rs4787956 IL4R G 0.34 0.99 0.83 to 1.18 1.11 0.84 to 1.46 1.03 0.91 to 1.17 0.611
rs16976728 IL4R A 0.38 0.92 0.77 to 1.10 1.07 0.82 to 1.39 1.00 0.88 to 1.13 0.978
rs480092 LSM2 G 0.16 1.25 1.04 to 1.51 1.30 0.81 to 2.08 1.21 1.04 to 1.42 0.015
rs2253820 PER1 A 0.17 1.02 0.9 to 1.16 0.72 0.52 to 1.00 0.96 0.87 to 1.06 0.412
rs4888201 PLCG2 A 0.16 1.10 0.91 to 1.34 1.39 0.77 to 2.51 1.13 0.95 to 1.33 0.168
rs10514519 PLCG2 A 0.18 1.06 0.88 to 1.28 1.59 0.92 to 2.75 1.11 0.95 to 1.31 0.195
rs4997772 PLCG2 A 0.39 1.13 0.95 to 1.35 1.07 0.84 to 1.37 1.05 0.94 to 1.18 0.377
rs3936112 PLCG2 A 0.39 0.98 0.87 to 1.10 0.97 0.82 to 1.16 0.98 0.91 to 1.07 0.700
rs4254419 PLD3 A 0.15 0.98 0.81 to 1.18 0.87 0.50 to 1.52 0.96 0.82 to 1.13 0.648
rs10758 SLC20A1 G 0.26 0.98 0.82 to 1.17 0.95 0.68 to 1.33 0.98 0.85 to 1.12 0.729
rs3825977 SMAD3 A 0.20 0.98 0.88 to 1.11 0.94 0.71 to 1.24 0.98 0.89 to 1.07 0.638
rs7166081 SMAD3 G 0.24 0.98 0.87 to 1.11 1.03 0.80 to 1.33 1.00 0.91 to 1.10 0.995
rs3777663 THEM2 G 0.24 1.02 0.86 to 1.22 1.17 0.84 to 1.63 1.05 0.92 to 1.20 0.453
rs2075642 TOMM40 A 0.20 0.97 0.81 to 1.16 1.06 0.69 to 1.63 0.99 0.86 to 1.15 0.931
rs12211125 VNN2/VNN3 G 0.09 0.96 0.83 to 1.11 1.19 0.73 to 1.94 0.99 0.87 to 1.12 0.882
MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval.
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beta signalling pathway, may contribute to increased
risk of breast cancer in BRCA2 mutation carriers. These
results suggest that the combinatorial approach may be
a useful method to prioritise candidate modifier genes
for polymorphism association studies.
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Additional file 1: Supplementary Table S1. Genes predicted to
modify risk. Genes predicted to modify risk in BRCA1 and/or BRCA2
mutation carriers by Walker and colleagues [18].
Additional file 2: Supplementary Table S2. List of 37 candidate
BRCA1/2 risk modifier SNPs. Each SNP listed was tagged to a gene and
shown to be associated with breast cancer risk from the CGEMS Study
version 1.
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rs10514519 PLCG2 A 0.18 0.85 0.66 to 1.09 1.92 0.95 to 3.88 0.99 0.79 to 1.24 0.933
rs4997772 PLCG2 A 0.39 1.21 0.95 to 1.55 1.26 0.89 to 1.78 1.14 0.97 to 1.34 0.107
rs3936112 PLCG2 A 0.39 0.91 0.76 to 1.09 0.94 0.73 to 1.22 0.96 0.85 to 1.08 0.483
rs4254419 PLD3 A 0.15 0.95 0.73 to 1.22 0.74 0.36 to 1.51 0.92 0.74 to 1.14 0.448
rs10758 SLC20A1 G 0.26 1.12 0.88 to 1.42 1.11 0.67 to 1.84 1.08 0.90 to 1.30 0.388
rs3825977 SMAD3 A 0.20 1.10 0.91 to 1.33 1.83 1.23 to 2.73 1.20 1.03 to 1.40 0.018
rs7166081 SMAD3 G 0.24 1.17 0.97 to 1.42 1.74 1.21 to 2.49 1.25 1.07 to 1.45 0.004
rs3777663 THEM2 G 0.24 0.95 0.75 to 1.21 1.11 0.69 to 1.79 0.99 0.82 to 1.20 0.945
rs2075642 TOMM40 A 0.20 1.14 0.89 to 1.46 1.19 0.68 to 2.09 1.12 0.92 to 1.37 0.267
rs12211125 VNN2 /VNN3 G 0.09 1.01 0.81 to 1.26 1.31 0.49 to 3.56 1.02 0.83 to 1.26 0.818
MAF, minor allele frequency; HR, hazard ratio; CI, confidence interval.
Figure 1 BRCA2 plot of relative risk for rs3825977 and
rs7166081 at the SMAD3 locus. BRCA2 plots of study group-
specific relative risk (RR) for rs3825977 and rs7166081 at the SMAD3
locus. Study groups with 70 or more carriers and tests of
heterogeneity are shown for (a) rs3825977 (overall RR (95%
confidence interval (CI)) = 1.20 (1.03, 1.40), Ptrend = 0.018) and (b)
rs7166081 (overall RR (95% CI) = 1.25 (1.07, 1.45), Ptrend = 0.004). OR,
odds ratio.
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